

View Article Online View Journal

MedChemComm

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: J. Gao, C. Fang, Z. Xiao, L. Huang, C. H. Chen, L. Wang and K. Lee, *Med. Chem. Commun.*, 2014, DOI:



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/medchemcomm

Published on 28 November 2014. Downloaded by Northeastern University on 29/11/2014 11:08:35

Discovery of novel 5-fluoro- N^2 , N^4 -diphenylpyrimidine-2, 4-diamines as potent inhibitors against CDK2 and CDK9

Jiadi Gao^{a,†}, Cheng Fang^{a,†}, Zhiyan Xiao^{a,*}, Li Huang^b, Chin-Ho Chen^b, Li-Ting Wang^c, Kuo-Hsiung Lee^{c,d}

^a Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

^b Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA

^c Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7568, USA

^d Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung, Taiwan

* To whom correspondence should be addressed. Corresponding author phone: +86-10-63189228;

E-mail: <u>xiaoz@imm.ac.cn</u>

[†] These authors contribute equally.

Based on a 3D-QSAR pharmacophore derived from a diverse set of known cyclin-dependent kinase 9 (CDK9) inhibitors and a composite pharmacophore extracted from the complex structure of flavopiridol (FVP)-CDK9, thirty novel 5-fluoro- N^2 , N^4 -diphenylpyrimidine-2,4-diamine derivatives were designed and synthesized. Initial tests against four tumor cell lines with the sulforhodamine B (SRB) assay identified a series of potent compounds with GI₅₀ values at lower micromolar or submicromolar level. Most of the highly cytotoxic compounds exhibited potent inhibitory activities against both CDK2/cyclin E1 and CDK9/cyclin T1. Notably, inhibitions against the two enzymes were generally correlated well with the cytotoxicity of these compounds. Appreciable inhibition was also observed for selected compounds in the anti-HIV-1 assay. Docking studies on compounds **6d** and **9g** provided conducive clues to further structural optimization.

Key words: 5-fluoro- N^2 , N^4 -diphenylpyrimidine-2, 4-diamines, cyclin-dependent kinases, pharmacophore, cytotoxicity, anti-HIV-1

Graphical Abstract



3D-QSAR pharmacophore derived from diverse CDK9 inhibitors



Composite pharmacophore revealed by the FVP-CDK9 complex structure



Novel CDK2/CDK9 inhibitors

Published on 28 November 2014. Downloaded by Northeastern University on 29/11/2014 11:08:35

1. Introduction

Cyclin-dependent kinases (CDKs) are a family of serine/threonine protein kinases involved in the control of cell cycle and the regulation of gene transcription. Once bound to the regulatory subunit cyclins, CDKs can phosphorylate the downstream substrates and activate various cellular processes. Due to their intense involvement in many physiological processes and diseases, CDKs have attracted extensive research interests¹. Several of the CDKs play critical roles in cell cycle progression and a number of CDK inhibitors are currently under clinical trials for the treatment of various cancers². As a member of the CDK family, CDK9 plays a pivotal role in transcriptional regulation and is regarded as a potential target in oncology, virology and cardiology³. CDK9 complexes with cyclin T to form transcription elongation factor b (P-TEFb) and regulate gene transcription by phosphorylating the C-terminus of the large subunit of RNA polymerase II. It has been reported that differential effects on HIV replication and T-cell activation were observed upon direct inhibition of the P-TEFb kinase activity in primary human peripheral blood lymphocytes⁴. Therefore, selective CDK9 inhibitors have been actively pursued⁵⁻⁹ and evaluated as potentially effective agents to block HIV-1 replication⁵⁻⁷. The X-ray crystal structures of these inhibitors complexed with CDK9 as well as CDK2 have been resolved and analyzed to investigate the structural basis for isotype selectivity¹⁰⁻¹². Nevertheless, recent studies^{13,14} have also suggested implication of CDK2 in HIV-1 transcription regulation through functional link with CDK9 (for example, by phosphorylating CDK9¹⁴). Therefore, compounds with good potency against CDK2 and CDK9 might be therapeutically useful in the treatment of cancer and HIV infection.

To search for new CDK inhibitors, especially CDK9 inhibitors as anti-cancer and anti-HIV agents, we have previously established quantitative pharmacophore models based on a diverse set of CDK9 inhibitors¹⁵. The most representative model depicted a pharmacophore with two hydrogen-bond acceptor features and two hydrophobic aromatic features. As illustrated in **Figure 1a**, such pharmacophore matches well with the chemical features of flavopiridol (FVP), a flavonoid

Published on 28 November 2014. Downloaded by Northeastern University on 29/11/2014 11:08:35

pan-CDK inhibitor and the most potent inhibitor against P-TEFb identified to date¹⁶. The interaction mode of FVP with CDK9 has been revealed by the crystal structure of the FVP-CDK9 complex¹⁷. As shown in **Figure 1b**, the FVP molecule occupies the ATP-binding site of CDK9. The O4 oxygen and the O5 hydroxyl of FVP form hydrogen bonds with the CDK9 hinge residues Cys106 and Asp104, respectively. An additional hydrogen bond is observed between the O3 hydroxyl and the Asp167 side chain. Moreover, the chloro-phenyl ring of FVP makes hydrophobic contacts with Ile25, and the protonated N1 of the piperidinyl group presents electrostatic interaction with Asp167. Therefore, a composite pharmacophore with three hydrogen bond forming atoms, one hydrophobic aromatic center and one positively charged center was constructed (**Figure 1c**). Remarkably, the quantitative and the composite pharmacophore models are in good consistency.



Figure 1. Pharmacophore models for CDK9 inhibitors. (a) a 3D-QSAR pharmacophore (with hydrogen-bond acceptors represented in green and hydrophobic aromatic features represented in cyan) derived from diverse CDK9 inhibitors and its mapping with FVP; (b) Key interactions between FVP and CDK9 revealed by their co-crystal structure; (c) a composite pharmacophore extracted from the interaction mode shown in (b). The hydrogen bond forming atoms are represented in green, the hydrophobic aromatic center is represented in cyan and the positively charged center is represented in purple.

We report herein the design, synthesis and biological evaluation of a series of novel

5-fluoro- N^2 , N^4 -diphenylpyrimidine-2,4-diamine derivatives. This novel class of compounds were designed by following a pharmacophore-oriented scaffold-hopping strategy. The hybrid pharmacophore combining key features in the 3D-QSAR and composite models demonstrated in Figure 1 was used to guide the molecular design (Figure 2). To ensure kinase inhibition and convey structural novelty, the 2-aminopyrimidine core structure, which is a privileged scaffold for CDK inhibitors^{8,18,19}, was utilized for the design. 5-Fluoro substitution was introduced according to previous structure-activity relationship studies CDK9 inhibitors with the on 2-anilino-4-heteroarylpyrimidine scaffold^{8,18}. The general formula and the pharmacophoric features of the target compounds are shown in Figure 2.



Figure 2. General formula of target compounds and their pharmacophoric features.

 R_1 contains a hydrogen bond forming atom and/or a positively charged center. Various R_2 and R_3 substituents are incorporated on the two phenyl rings to meet the pharmacophoric requirements.

2. Results and discussion

2.1 Chemistry

The general synthetic route for compounds **6a-6f** was shown in **Scheme 1**. Compound **2a** was prepared through a cross-coupling reaction between 1-bromo-3-nitrobenzene (**1a**) and morpholine²⁰, and then followed by catalytic hydrogenation to afford compound **3a**. Compounds **3b** and **3c** were synthetized similarly. Compounds **5a-5d** were prepared by regio-selective substitution of the appropriate amines to 2,4-dichloro-5-fluoropyrimidine²¹. Further substitutions between **3a-3c** and **5a-5d** in alcoholic solvent afforded the target compounds **6a-6f**²².



Scheme 1. Reagents and conditions: a. morpholine or *N*-methyl piperazine, CuI, *L*-proline, K_2CO_3 , DMSO, N₂, 100-110°C; b. Pd/C, H₂, CH₃OH or THF; c. the appropriate amine, Et₃N, EtOH; d. CF₃COOH, *i*-PrOH or 2-BuOH, reflux; e. 3-Nitroaniline (for 7) or 3-aminobenzoic acid (for 10), CF₃COOH, *i*-PrOH or 2-BuOH, reflux; f. the appropriate acid or amine, DIEA, HATU, DMF.

The preparation of compounds 9a-9h and 11a-11p was also illustrated in Scheme 1. Compound

5b was reacted with *m*-nitroaniline and *m*-aminobenzoic acid to give compounds **7** and **10**, respectively. Catalytic hydrogenation of compound **7** in the presence of Pd/C produced compound **8**. Both **8** and **10** were subjected to condensation reactions under the treatment of 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium hexafluorophosphate (HATU) and *N*,*N*-diisopropylethylamine (DIEA) to afford the target amide compounds **9a-9h** and **11a-11p**²³.

2.2 Biological evaluation

All the target compounds were initially tested against the tumor cell lines of A594, DU145, KB and KBvin with the sulforhodamine B (SRB) assay. The inhibitory activities of the compounds in terms of GI₅₀ values were shown in **Tables 1, 2 and 3**.

The cytotoxic results suggested that fluoro-substitution on 4-anilino might be important for the anti-proliferative effects (**6a** and **6b** *versus* **6c** and **6d**). Therefore, *p*-fluoroanilino was retained at R_2 , while methoxyl substitution was introduced at R_3 (**6e**), and morpholino was further replaced with 4-methylpiperazin-1-yl (**6f**) to explore their effects on cytotoxicity. Although the introduction of methoxyl group at R_3 decreased the inhibitory activity (**6c** *versus* **6e**), the presence of 4-methylpiperazin-1-yl instead of morpholino at R_1 significantly increased potency (**6e** *versus* **6f**). Such observation implicated that the electrostatic interaction between the residue Asp167 and the protonated nitrogen in the piperidinyl group is more advantageous over the hydrogen bonding interaction between the oxygen atom in the morpholino moiety and Asp167. Therefore, positively charged atoms should be preferred in the close proximity to R_1 .

Compounds **9a-9h** and **11a-11p** retained the *p*-fluoroanilino at R_2 , while incorporating diverse R_1 substituents with different sizes, electronic effects and hydrogen bond forming capability to further investigated the structure-activity relationships at this molecular area. For both compounds **9** and **11**, aliphatic substituents, either linear or cyclic, were generally favored over aromatic substituents at R_1 . The results implied that the R_1 substituents might serve as a counterpart of the

sugar moiety in the ATP structure, therefore, aliphatic substituents might be more likely to meet the requirements for optimal pharmacophoric orientation and molecular shape of CDK inhibitors. In addition, compounds with a positively charged center were more potent than their congeners with only hydrogen bond forming atoms (**9g** *versus* **9h**; **11a** *versus* **11b**; **11f** *versus* **11g**), which suggests the importance of electrostatic interactions in this molecular area. The series **9** were generally more potent than the series **11**. For compounds with aromatic substituents at R₁ of **9**, electron-withdrawing groups might be preferred over electron-donating moieties for cytotoxicity (**9b** *versus* **9c**; **9a** *versus* **9d**). However, electrostatic properties showed no definite effects on the cytotoxicity of compounds in series **11**.

Comnd	R ₂	GI ₅₀ (μM) ^a				
compu.		A549 ^b	DU145	KB	KBvin	
6a		11.59 ± 1.03	> 10 ^c	14.80 ± 1.02	22.47 ± 2.46	
6b	şCI ₹CI	12.02 ± 0.90	> 10	> 10	> 10	
6c	ξ-√_−F	3.83 ± 1.18	> 10	> 10	> 10	
6d	F	1.09 ± 0.46	4.24 ± 1.05	> 10	> 10	
6e	Ş-√F	18.28 ± 3.34	> 10	> 10	> 10	
6f	Ş-√_F	1.13 ± 0.61	0.91 ± 0.12	0.96 ± 0.21	0.91 ± 0.30	
FVP	-	0.14 ± 0.007	0.15 ± 0.007	0.16 ± 0.007	0.18 ± 0.005	

Table 1. Inhibitory activities of compounds 6a-6f against tumor cell growth.

^a The GI₅₀ values are the average of three independent measurements;

^b Cell lines: A549 (lung cancer), DU-145 (prostate cancer), KB (nasopharyngeal carcinoma) and

KBvin (vincristine-resistant KB subline);

 $^{\circ}$ No significant inhibition against tumor cell growth was observed under the concentration of 10 μ M.

Compd	R.	GI ₅₀ (μM) ^a			
compu.	тц	A549 ^b	DU145	KB	KBvin
9a	£	37.82 ± 4.88	> 10 °	> 10	> 10
9b	NO ₂	7.25 ± 0.96	12.62 ± 0.70	15.10 ± 1.16	11.35 ± 2.08
9c	§−√−N	> 10	> 10	> 10	> 10
9d	₹ N	1.65 ± 0.67	4.33 ± 2.39	5.28 ± 3.49	4.57 ± 2.58
9e	₹ N	10.29 ± 1.98	26.38 ± 4.57	23.55 ± 3.92	20.10 ± 2.95
9f	₹ \ N	1.33 ± 0.10	1.15 ± 0.33	1.70 ± 0.80	11.93 ± 1.92
9g	NN	1.18 ± 0.13	1.21 ± 0.08	1.26 ± 0.05	1.81 ± 0.60
9h	[≹] 0−	2.05 ± 0.52	4.46 ± 0.70	6.25 ± 1.38	3.94 ± 1.04
FVP	-	0.14 ± 0.007	0.15 ± 0.007	0.16 ± 0.007	0.18 ± 0.005

 Table 2. Inhibitory activities of compounds 9a-9h against tumor cell growth

^a The GI₅₀ values are the average of three independent measurements.

^b Cell lines: A549 (lung cancer), DU-145 (prostate cancer), KB (nasopharyngeal carcinoma) and KBvin (vincristine-resistant KB subline);.

^c No significant inhibition against tumor cell growth was observed under the concentration of 10 μ M.

Table 3. Inhibitory activities of compounds 11a-11p against tumor cell growth

10

Published on 28 November 2014. Downloaded by Northeastern University on 29/11/2014 11:08:35.

_

Comnd	R ₁	GI ₅₀ (μM) ^a			
compu.		A549 ^b	DU145	KB	KBvin
11a	§−N_O	11.21 ± 2.06	11.94 ± 0.81	14.58 ± 2.93	13.05 ± 2.24
11b	ξ−N_N−	9.07 ± 1.30	10.89 ± 0.82	12.58 ± 3.05	12.27 ± 1.90
11c	ξ−N	13.21 ± 1.45	13.02 ± 0.65	14.78 ± 2.53	13.81 ± 0.87
11d		12.22 ± 1.95	17.91 ± 1.09	20.29 ± 4.09	> 10 ^c
11e	s st N N	9.96 ± 0.60	15.65 ± 1.44	14.88 ± 2.20	16.68 ± 1.46
11f	HNN	1.45 ± 0.07	4.34 ± 1.40	4.16 ± 0.69	7.26 ± 3.65
11g	HNOH	11.85 ± 2.08	13.38 ± 2.60	12.39 ± 2.48	21.40 ± 2.38
11h	HN-CF3	> 10	> 10	> 10	> 10
11i		> 10	>10	> 10	>10
11j	HN-O	11.03 ± 0.52	>10	> 10	15.71 ± 1.38
11k		13.85 ± 0.15	13.67 ± 1.72	15.47 ± 1.58	12.74 ± 1.65
111		12.86 ± 0.71	11.58 ± 0.18	14.08 ± 0.79	12.01 ± 1.66
11 m		17.45 ± 2.49	17.50 ± 3.03	20.08 ± 1.06	20.73 ± 3.14
11n	HN-	15.30 ± 0.86	15.06 ± 1.54	20.03 ± 10.96	13.67 ± 1.59
110	HN N	> 10	> 10	> 10	> 10

11p		10.12 ± 0.80	15.10 ± 2.27	14.57 ± 1.70	13.12 ± 0.96
FVP	-	0.14 ± 0.007	0.15 ± 0.007	0.16 ± 0.007	0.18 ± 0.005

^a The GI₅₀ values are the average of three independent measurements.

Published on 28 November 2014. Downloaded by Northeastern University on 29/11/2014 11:08:35.

^b Cell lines: A549 (lung cancer), DU-145 (prostate cancer), KB (nasopharyngeal carcinoma) and KBvin (vincristine-resistant KB subline);.

^c No significant inhibition against tumor cell growth was observed under the concentration of 10 μ M.

Nine of the most cytotoxic compounds were further evaluated against CDK2/cyclin E1 and CDK9/cyclin T1. Most of these compounds exhibited potent inhibitory activities against both systems (**Table 4**). Due to limited data, it is difficult to deduce informative SAR from the results. However, for most compounds, the molecular potency generally correlated well with the cellular cytotoxicity, which indicated that CDK inhibition might be responsible for the cytotoxicity of these compounds. Compound **6f** was the only exception. The discrepancy between cellular and molecular activities of compound **6f** implicated the involvement of alternative molecular mechanisms other than CDK inhibition. For all the compounds tested at molecular level, only compounds **6d** and **9d** showed moderate selectivity to CDK9 over CDK2.

Comnd	IC ₅₀ (μM) [*]		
Compu.	CDK2/CyclinE1	CDK9/CyclinT1	
6d	5.85	0.33	
6f	> 10 #	> 10	
9d	15.30	2.57	
9f	1.24	2.45	
9g	1.71	0.78	

Table 4. Inhibitory activities of selected compounds against CDK2/cyclin E1 and CDK9/cyclin T1

9h	3.27	2.02
11b	22.10	11.30
11e	60.60	15.60
11f	4.65	1.72
FVP	0.13	4.59 (nM)

* The IC_{50} value was interpolated from dose-response data with at least six different concentrations. Each test was performed in duplicate. Data represent the average of duplicate measurements.

[#]No significant inhibition was observed at the concentration of 10 μ M.

To determine whether selective CDK9 inhibition correlates with anti-HIV activity, three compounds (**6d**, **11e** and **11f**) with different level of selectivity to CDK9 were tested in an anti-HIV-1 assay. Appreciable inhibition was observed for all three compounds. Notably, the results did reveal a trend that higher selectivity to CDK9 might lead to better therapeutic index (**Table 5**). Further validation with more CDK9 inhibitors is undergoing.

Table 5. Anti-HIV-1	activities	of selected	compounds.
---------------------	------------	-------------	------------

Compd.	EC_{50}^{*}	IC_{50}^{*}	Selectivity	$\mathrm{TI}^{\#}$
	(μ)	M)	CDK2/CDK9	
6d	1.37 ± 0.42	10.22 ± 1.27	17.7	7.45
11e	7.08 ± 1.54	15.45 ± 1.72	3.9	2.18
11f	3.15 ± 0.66	3.40 ± 0.27	2.7	1.08
FVP	0.015 ± 0.005	0.067 ± 0.007	28.3	4.47

^{*} The EC₅₀ and IC₅₀ values are the average of three independent measurements;

[#] TI, the rapeutic index, the ratio of the IC_{50} value to the EC_{50} value.

2.3 Molecular modeling

Docking studies on selected compounds were performed to recognize their interaction modes with CDKs. As exemplified by the docking poses of compound **9g** in the ATP-binding sites of CDK9, two alternative binding poses were suggested (**Figure 3**). For pose A (**Figure 3a**), the molecule assumed an orientation similar to that of FVP. Besides the hydrogen bond between N-1 atom of the pyrimidine ring and Cys106, additional hydrogen bonds were observed between the 2-amino and Asp104, as well as the carboxyl oxygen and Asp167. Electrostatic interaction between the nitrogen in *N*,*N*-dimethyl glycine and Asp167 were also monitored. Alternatively, compound **9g** could also adopt pose B (**Figure 3b**). It was a turnover of pose A, where the *N*,*N*-dimethyl glycine moiety occupied the hydrophobic subpocket engaged by the chloro-phenyl of FVP. The N-1 atom and 2-amino moiety on the pyrimidine ring interacted with the hinge residue Cys106 of CDK9 through hydrogen bonding, while the 4-anilino group protruded toward Asp167. The electron-withdrawing fluoro-substitution on N^4 -phenyl made it electron deficient and presented electrostatic interaction with Asp 167. The disclosure of alternative binding poses of this compound class might provide new clues for further structural optimization.



Published on 28 November 2014. Downloaded by Northeastern University on 29/11/2014 11:08:35.



Figure 3. Alternative interaction modes of 9g as suggested by the docking study.

Compound **6d**, the inhibitor with the highest selectivity toward CDK9, was docked to both CDK2 and CDK9 to provide insights on structural basis for selective CDK9 inhibition. As shown in **Figure 4**, compound **6d** bound to the ATP sites of CDK2 and CDK9 with an orientation different from that of FVP. It adopted a pose similar to pose B in **Figure 3b**. The prevalence of pose B for **6d** could be attributed to its structural features in R_1 and R_2 . Due to the absence of protonable nitrogen in R_1 , the electrostatic interaction between R_1 and Asp145 in CDK2 or Asp167 in CDK9 was missed. On the other hand, the electron-withdrawing diffuoro-substitution (R_2) on N^4 -phenyl strengthened its interaction with Asp145 (CDK2) or Asp167 (CDK9).







Figure 4. Interaction modes of 6d with CDK2 (a) and CDK9 (b) as suggested by the docking study.

As indicated in **Figure 4**, the key interactions of **6d** in CDK2 and CDK9 were similar. Hydrogen bonds existed between N-1 atom/2-amino moiety of **6d** and the hinge residue (Leu83 for CDK2 and Cys105 for CDK9). The difluoro-substituted N^4 -phenyl ring extended to the proximity of Asp145 (CDK2) or Asp167 (CDK9). The most obvious difference between the interaction modes of **6d** with CDK2 and CDK9 was the orientation of the morpholino ring in R₁. Compound **6d** assumed a

condensed U-conformation in the ATP-binding site of CDK2, and the morpholino ring was virtually parallel to the N^4 -phenyl ring (**Figure 4a**). While, it was more extended in the binding site of CDK9 and the morpholino ring was basically vertical to the N^4 -phenyl ring. The changing of the Lys89 in CDK2 to Gly122 in CDK9 was responsible for the discrepancy in the interaction modes. Due to such a difference, the binding site of CDK9 is relatively larger and can accommodate more steric moieties in R₁. The lone pair interaction between the nitrogen atom in morpholino and the Lys89 in CDK2 might cause further shift of the morpholino ring toward the N^4 -phenyl. The structural insights gained from docking studies might guide further molecular design of selective CDK9 inhibitors.

3. Experimental

3.1 Materials and methods

All reactions were monitored by thin-layer chromatography with pre-coated silica gel F254 plates purchased from Merck, Inc. All melting points were determined on Yanaco Melting point apparatus and are uncorrected. Mass spectra (MS) were taken in HR-ESI mode on Exactive PlusTM LC/MSD Orbitrap from Thermo Fisher Scientific. ¹H-NMR spectra were recorded on Varian Mercury 300-MHz spectrometer. Chemicals were obtained from local suppliers and were used without further purification.

3.2 Chemistry

3.2.1 Preparation of compound 3

2-Nitro-4-bromoanisole (2.32 g, 10 mmol), morpholine (3.58 g, 40 mmol), CuI (0.19 g, 0.1 mmol), *L*-proline (0.23 g, 2 mmol) and K_2CO_3 (2.76 g, 20 mmol) were dissolved in 20 ml DMSO and stirred under nitrogen for 48 h at 100 °C. After cooling to room temperature, the reaction mixture was poured into water and extracted with ethyl acetate, the combined organic layers were successively washed by water and saturated solution of Na₂CO₃. The organic layer was dried over Na₂SO₄, and

Page 18 of 30

Medicinal Chemistry Communications Accepted Manuscript

filtered. The solvents were removed under reduced pressure and the crude material was purified by column chromatography on silica gel, eluted with petroleum ether/ethyl acetate (10:1) to afford compound **2b** as a yellow oil (1 g, 42%).

Compound **2b** (1 g, 4.8 mmol) and Pd/C (0.1 g) were added in methanol and stirred under hydrogen atmosphere for 24 h at room temperature. Pd/C was filtered by diatomite and the solvents were removed under reduced pressure. The crude material was purified by column chromatography on silica gel, eluted with petroleum ether/ethyl acetate (2:1) to afford compound **3b** as a white solid (0.3 g, 34%).

Compounds **3a** and **3c** were synthetized from different start materials using the same procedure as described.

3.2.2 Preparation of compound 5

2,4-Dichloro-5-fluoro-uricpyrimidine (4, 1.67 g, 10 mmol), *p*-fluoro-aniline (1.11 g, 10 mmol) and trifluoroacetic acid (1.52 g, 15 mmol) were mixed in 10 ml ethanol and stirred for 24 h at room temperature. The precipitation was filtered and then washed by ethanol, dried over Na_2SO_4 , and filtered. The solvents were removed under reduced pressure getting **5b** as a white solid (2.4 g, 99%).

Compound 5a, 5c and 5d were synthetized from different starting materials with the same procedure as described.

3.2.3 Preparation of compound 6

To a solution of compound **3a** (122 mg, 0.687 mmol) and compound **5d** (200 mg, 0.687 mmol) in 10 ml isopropanol, one drop of acetic acid was added. The reaction mixture was stirred at 110 $^{\circ}$ C and was refluxed for 24 h. After cooling to room temperature, the precipitation was filtered to get compound **6d** as a white solid (200 mg, 40%).

Compounds 6a-6c and 6e-6f were synthetized from different starting materials using the same

Published on 28 November 2014. Downloaded by Northeastern University on 29/11/2014 11:08:35

procedure as described.

Compound 6a: yield: 67 %, mp: 189-190°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 10.07 (s, 1H), 9.74 (s, 1H), 8.28 (d, *J* = 3.9 Hz, 1H), 7.87 (s, 2H), 7.31 (s, 1H), 7.15-7.18 (m, 3H), 6.74 (s, 1H), 3.74 (s, 4H), 3.08 (s, 4H). HR-ESI-MS: *m/z* = 434.0942 [M+H]⁺, calcd for C₂₀H₁₉N₅OFCl₂: 434.0945.

Compound 6b: yield: 90%, mp: 196-198°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 10.40 (s, 1H), 10.14 (s, 1H), 8.32 (d, *J* = 4.2 Hz, 1H), 8.04 (d, *J* = 1.8 Hz, 1H), 7.72 (d, *J* = 7.2 Hz, 1H), 7.56 (d, *J* = 8.7 Hz, 1H), 7.18-7.25 (m, 2H), 7.09 (d, *J* = 7.5 Hz, 1H), 6.81 (d, *J* = 6.6 Hz, 1H), 3.73 (s, 4H), 3.06 (s, 4H). HR-ESI-MS: $m/z = 434.0952 [M+H]^+$, calcd for C₂₀H₁₉N₅OFCl₂: 434.0945.

Compound 6c: yield: 47%, mp: 220-222°C, ¹H-NMR (300 MHz, DMSO- d_6): δ 9.36 (s, 1H), 9.03 (s, 1H), 8.08 (d, J = 3.6 Hz, 1H), 7.78 (dd, J = 5.1, 9.3 Hz, 2H), 7.21 (s, 1H), 7.12 (t, J = 6.6 Hz, 3H), 7.05 (t, J = 8.1 Hz, 1H), 6.50 (d, J = 7.5 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 2.96 (t, J = 4.8 Hz, 4H). HR-ESI-MS: m/z = 384.1625 [M+H]⁺, calcd for C₂₀H₂₀N₅OF₂: 384.1630.

Compound 6d: yield: 40%, mp: 181-183°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 9.19 (s, 1H), 8.92 (s, 1H), 8.10 (d, *J* = 3.3 Hz, 1H), 7.36-7.43 (m, 1H), 7.22 (t, *J* = 8.1 Hz, 2H), 7.02 (t, *J* = 8.4 Hz, 2H), 6.85 (t, *J* = 8.1 Hz, 1H), 6.41 (d, *J* = 6.9 Hz, 1H), 3.66 (t, *J* = 4.8 Hz, 4H), 2.90 (t, *J* = 4.8 Hz, 4H). HR-ESI-MS: $m/z = 402.1534 [M+H]^+$, calcd for C₂₀H₁₉N₅OF₃: 402.1536.

Compound 6e: yield: 23%, mp: 195-198°C, ¹H NMR (400MHz, DMSO-*d*₆): δ 9.40 (s,1H), 8.09(d, *J* = 3.6 Hz,1H), 7.70-7.67 (m,4H), 7.12 (t, *J* = 8.8 Hz, 2H), 6.88 (d, *J* = 8.8 Hz, 1H), 6.51 (dd, *J* = 2.8, 8.8 Hz, 1H), 3.76 (s, 3H), 3.64 (t, *J* = 4.4 Hz, 4H), 2.82 (t, *J* = 4.4 Hz, 4H). HR-ESI-MS: *m/z* = 414.1728 [M+H]⁺, calcd for C₂₀H₂₁N₂O₅: 414.1736.

Compound 6f: yield: 21%, mp: 71-73°C, ¹H-NMR (300 MHz, DMSO- d_6): δ 9.40 (s, 1H), 8.09 (d, J = 5.4 Hz, 1H), 7.71-7.64 (m, 4H), 7.11 (t, J = 8.5 Hz, 2H), 6.86 (d, J = 9.0 Hz, 1H), 6.52 (dd, J = 3.9, 5.4 Hz, 1H), 3.75 (s, 3H), 2.87 (m, 4H), 2.38 (m, 4H), 2.20 (s, 3H). HR-ESI-MS: m/z = 427.2040 [M+H]⁺, calcd for C₂₂H₂₅N₆O F₂: 427.2052.

3.2.4 Preparation compound 8

Compound **5b** (2.42 g, 10 mmol), *m*-nitroaniline (1.38 g, 10 mmol) and trifluoroacetic acid (1.14 g, 10 mmol) were mixed in 10 ml isopropanol and stirred under reflux for 24 h. After cooling to room temperature, the precipitation was filtered and recrystallized in CH_2Cl_2 to afford a light yellow solid 2.5 g (7).

Compound 7 (2.5 g, 7.2 mmol) and Pd/C (0.25 g) were added in a mixture of methanol and THF, and stirred under hydrogen atmosphere for 24 h at room temperature. Pd/C was filtered by diatomite and the solvents were removed under reduced pressure and the crude material was recrystallized in CH_2Cl_2 to afford compound 8 as a light yellow solid (2.0 g, yield for two steps: 64%).

3.2.5 Preparation compound 9

Compound **8** (150 mg, 0.479 mmol) and pyrazine-2-carboxylic acid (65.3 mg, 0.527 mmol) were dissolved in a mixture of CH_2Cl_2 and THF. HATU (218.5 mg, 0.576 mmol) and DIEA (379 mg, 2.874 mmol) were then added. The reaction mixture was stirred at room temperature for 24 h, and was then poured into icy water. The precipitation was filtered and washed by dry methanol for several times to afford compound **9e** as a white solid (101 mg, 51%).

Compounds **9a-9d** and **9f-9h** were synthetized from different start materials using similar procedure as described.

Compound 9a: yield: 43%, mp: 253-255°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 10.16 (s, 1H), 9.37 (s, 1H), 9.25 (s, 1H), 8.10 (d, *J* = 3.3 Hz, 1H), 8.04 (s, 1H), 7.93 (d, *J* = 6.9 Hz, 2H), 7.85 (dd, *J* = 5.7, 8.7 Hz, 2H), 7.49-7.58 (m,3H), 7.41 (d, *J* = 8.1Hz, 1H), 7.26 (t, *J* = 7.5 Hz, 1H), 7.19 (t, *J* = 7.8 Hz, 1H), 7.08 (t, *J* = 9.0 Hz, 2H). HR-ESI-MS: $m/z = 418.1478 [M+H]^+$, calcd for C₂₃H₁₈N₅OF₂: 418.1474.

Compound 9b: yield: 33%, mp: 242-243°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 10.50 (s, 1H), 9.39 (s, 1H), 9.30 (s, 1H), 8.77 (s, 1H), 8.41 (dd, *J* = 9.0, 12.9 Hz, 2H), 8.09 (d, *J* = 10.2 Hz, 2H), 7.84 (t, *J* = 6.9 Hz, 3H), 7.42 (d, *J* = 7.2 Hz, 1H), 7.20-7.30 (m, 2H), 7.07 (t, *J* = 8.4 Hz, 3H). HR-ESI-MS: *m/z* = 463.1329 [M+H]⁺, calcd for C₂₃H₁₇N₆O₃F₂: 463.1325.

Compound 9c: yield: 99%, mp: > 285°C, ¹H NMR (300MHz, DMSO-*d*₆): δ 9.77 (s, 1H), 9.34 (s, 1H), 9.18 (s, 1H), 8.08 (d, *J* = 3.6 Hz, 2H), 7.98 (s, 1H), 7.86-7.81 (m, 3H), 7.35 (d, *J* = 8.1 Hz, 1H), 7.24 (d, *J* = 8.4 Hz, 1H), 7.17-7.04 (m, 3H), 6.73 (d, *J* = 9 Hz, 2H), 2.98 (s, 6H). HR-ESI-MS: *m/z* = 461.1885[M+H]⁺, calcd for C₂₀H₂₁N₂O₅: 461.1896.

Compound 9d: yield: 48%, mp: 280°C (dec.), ¹H NMR (400MHz, DMSO- d_6): δ 10.40 (s, 1H), 9.38 (s, 1H), 9.28 (s, 1H), 8.77 (d, J = 5.2 Hz, 2H), 8.10 (d, J = 3.6 Hz, 1H), 8.04 (s, 1H), 7.84-7.81 (m, 4H), 7.43 (d, J = 8 Hz, 1H), 7.28-7.19 (m, 2H), 7.10-7.06 (m, 2H). HR-ESI-MS: $m/z = 419.1414[M+H]^+$, calcd for C₂₀H₂₁N₂O₅: 419.1426.

Compound 9e: yield: 51%, mp: 265-266°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 10.47 (s,1H), 9.39 (s, 1H), 9.28 (d, *J* = 10.2 Hz, 2H), 8.92 (s, 1H), 8.79 (s, 1H), 8.12 (dd, *J* = 3.6, 10.2 Hz, 2H), 7.09 (m, 2H), 7.38 (d, *J* = 7.5 Hz, 2H), 7.22 (t, *J* = 8.1 Hz, 1H), 7.07 (t, *J* = 8.7 Hz, 2H). HR-ESI-MS: *m/z* = 420.1381 [M+H]⁺, calcd for C₂₁H₁₆N₇OF₂: 420.1379.

Compound 9f: yield: 35%, mp: 272°C (dec.), ¹H-NMR (300 MHz, DMSO-*d*₆): δ 9.73 (s, 1H), 9.36 (s, 1H), 9.17 (s, 1H), 8.08 (d, *J* = 3.6 Hz, 1H), 7.81-7.87 (m, 3H), 7.32 (d, *J* = 8.4 Hz, 1H), 7.07-7.18 (m, 4H), 2.82 (d, *J* = 11.1 Hz, 2H), 2.17 (s, 3H), 1.88 (t, *J* = 9.6 Hz, 2H), 1.60-1.69 (m, 4H). HR-ESI-MS: *m/z* = 439.2055 [M+H]⁺, calcd for C₂₃H₂₅N₆OF₂: 439.2052.

Compound 9g: yield: 48%, mp: 206-208°C, ¹H-NMR (300 MHz, DMSO- d_6): δ 9.50 (s, 1H), 9.36 (s, 1H), 9.19 (s, 1H), 8.08 (d, J = 3.6 Hz, 1H), 7.85-7.82 (m, 3H), 7.36 (d, J = 8.4 Hz, 1H), 7.19 (d, J = 8.4 Hz, 1H), 7.20-7.10 (m, 3H), 3.04 (s, 2H), 2.26 (s, 6H). HR-ESI-MS: m/z = 399.1743 [M+H]⁺, calcd for C₂₀H₂₁N₆OF₂: 399.1739.

3.2.6 Preparation compound 10

Compound **5d** (2.42 g, 10 mmol), *m*-aminobenzoic acid (1.37 g, 10 mmol) and trifluoroacetic acid (1.14 g, 10 mmol) were mixed in 15 mL isopropanol and was stirred under reflux for 24 h. After cooling to room temperature, the precipitation was filtered and washed by CH_2Cl_2 for several times to afford compound **10** as a white solid (2.5 g, 73%).

3.2.7 Preparation compound 11

Compound **10** (200 mg, 0.585 mmol) and morpholine (62 mg, 0.702 mmol) were dissolved in DMF, HATU (267 mg, 0.702 mmol) and DIEA (302 mg, 2.34 mmol) were then added. The reaction mixture was stirred at room temperature for 24 h and then was poured into icy water. The precipitation was filtered to afford compound **11a** as a white solid (188 mg, 78%).

Compound **11b-11p** were synthetized from different start materials using similar procedure as described.

Compound 11a: yield: 78%, mp: 174-176°C, ¹H NMR (300MHz, DMSO-*d*₆): δ 9.42 (s, 1H), 9.37 (s, 1H), 8.12 (d, *J* = 3.6 Hz, 1H), 7.78-7.74 (m, 3H), 7.65 (d, *J* = 7.5 Hz, 1H), 7.27 (t, *J* = 7.8 Hz, 1H), 7.15 (t, *J* = 8.7 Hz, 2H), 6.89 (d, *J* = 7.8 Hz, 1H), 3.55 (m, 6H), 3.31 (m, 2H). HR-ESI-MS: *m/z* = 412.1574[M+H]⁺, calcd for C₂₀H₂₁N₂O₅: 412.1580.

Compound 11b: yield: 24%, mp: 184-185°C, ¹H NMR (300MHz, DMSO-*d*₆): δ 9.42 (s, 1H), 9.37 (s, 1H), 8.12 (d, *J* = 3.6 Hz, 1H), 7.78-7.74 (m, 3H), 7.65 (d, *J* = 8.1 Hz, 1H), 7.26 (t, *J* = 7.8 Hz, 1H), 7.15 (t, *J* = 8.7 Hz, 2H), 6.86 (d, *J* = 7.8 Hz, 1H), 3.57 (s, 2H), 3.31 (s, 2H), 2.26 (s, 4H), 2.16 (s, 3H).

Medicinal Chemistry Communications Accepted Manuscript

HR-ESI-MS: $m/z = 425.1883[M+H]^+$, calcd for C₂₀H₂₁N₂O₅: 425.1896.

Compound 11c: yield: 73%, mp: 197-199°C, ¹H-NMR (300 MHz, DMSO- d_6): δ 9.41 (s, 1H), 9.35 (s, 1H), 8.12 (d, J = 3.6 Hz, 1H), 7.74-7.79 (m, 3H), 7.64 (d, J = 8.1 Hz, 1H), 7.25 (t, J = 8.1 Hz, 1H), 7.15 (t. J = 8.4 Hz, 2H), 6.84 (d, J = 7.5 Hz, 1H), 3.54 (brs, 2H), 3.24 (brs, 2H), 1.39-1.58 (brs, 6H). HR-ESI-MS: $m/z = 410.1794 [M+H]^+$, calcd for C₂₂H₂₂N₅OF₂: 410.1787.

Compound 11d: yield: 78%, mp: 263-265°C, ¹H-NMR (300 MHz, DMSO- d_6): δ 9.42 (s, 1H), 9.38 (s, 1H), 8.12 (d, J = 3.6 Hz, 1H), 7.76 (t, J = 5.1 Hz, 3H), 7.68 (d, J = 8.4 Hz, 1H), 7.28 (t, J = 8.1 Hz, 1H), 7.16 (t, J = 8.7 Hz, 2H), 6.92 (d, J = 7.2 Hz, 1H), 3.55-3.80 (brs, 2H), 3.35-3.50 (brs, 2H), 3.00-3.20 (brs, 4H), 2.89(s, 3H). HR-ESI-MS: $m/z = 489.1518 [M+H]^+$, calcd for $C_{22}H_{23}N_6O_3F_2S$: 489.1515.

Compound 11e: yield: 39%, mp:161-163°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 9.42 (s, 1H), 9.37 (s, 1H), 8.12 (d, J = 3.0 Hz, 1H), 7.74-7.79 (m, 3H), 7.63 (d, J = 7.2 Hz, 1H), 7.26 (t, J = 7.5 Hz, 1H), 7.13 (t, J = 4.2 Hz, 2H), 6.76-6.83 (m, 1H), 3.50-3.61 (m, 3H), 3.40-3.45 (m, 3H), 1.97-2.02 (m, 3H), 1.79-1.85 (m, 2H), 1.63 (s, 1H), 1.49 (s, 1H). HR-ESI-MS: $m/z = 467.2015 [M+H]^+$, calcd for C₂₄H₂₅N₆O₂F₂: 467.2002.

Compound 11f: yield: 34%, mp: 174-176°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 9.39 (s, 1H), 9.32 (s, 1H), 8.20 (m, 1H), 8.10 (d, J = 3.6 Hz, 1H), 8.02 (s, 1H), 7.83-7.75 (m, 3H), 7.34-7.25 (m, 2H), 7.11 (t, J = 8.7 Hz, 2H), 2.36 (t, J = 7.2 Hz, 4H), 2.16 (m, 6H). HR-ESI-MS: m/z = 413.1899 [M+H]⁺, calcd for C₂₁H₂₃N₆OF₂: 413.1896.

Compound 11g: yield: 67%, mp: 212-214°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 9.39 (s, 1H), 9.32 (s, 1H), 8.26 (t, J = 5.4 Hz, 1H), 8.11 (d, J = 3.9 Hz, 1H), 8.08 (s, 1H), 7.79-8.83 (m, 2H), 7.34 (t, J = 3.9 Hz, 1H), 8.08 (s, 1H), 7.79-8.83 (m, 2H), 7.34 (t, J = 3.9 Hz, 1H), 8.11 (d, 7.8 Hz, 1H), 7.29 (t, J = 7.8 Hz, 1H), 7.11 (t, J = 8.7 Hz, 2H), 4.69 (t, J = 5.7 Hz, 1H), 3.48 (dd, J =6.3, 9.0 Hz, 2H), 3.29 (t, J = 6.0 Hz, 1H). HR-ESI-MS: m/z = 386.1431 [M+H]⁺, calcd for C₁₉H₁₈N₅O₂F₂: 386.1423.

Compound 11h: yield: 5.7%, mp:247-248°C, ¹H-NMR (300 MHz, DMSO- d_6): δ 10.51 (s, 1H), 9.42

(d, J = 5.7 Hz, 1H), 9.41 (s, 1H), 8.13-8.17 (dd, J = 3.9, 12.0 Hz, 2H), 7.98 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 6.9 Hz, 1H), 7.79 (dd, J = 4.8, 9.0 Hz, 2H), 7.71 (d, J = 9.3 Hz, 2H), 7.47 (d, J = 8.1 Hz, 1H), 7.38 (t, J = 7.5 Hz, 1H), 7.07 (t, J = 8.7 Hz, 2H). HR-ESI-MS: m/z = 486.1362 [M+H]⁺, calcd for C₂₄H₁₇N₅OF₅: 486.1348.

Compound 11i: yield: 50%, mp: 269-271°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 9.98 (s, 1H), 9.37 (s, 1H), 8.11 (t, *J* = 3.6 Hz, 2H), 7.81 (t, *J* = 8.7 Hz, 3H), 7.61 (d, *J* = 8.7 Hz, 2H), 7.44 (d, *J* = 8.4 Hz, 1H), 7.34 (t, *J* = 7.5 Hz, 1H), 7.09 (t, *J* = 8.7 Hz, 2H), 6.92 (d, *J* = 8.7 Hz, 2H), 3.72 (t, *J* = 4.8 Hz, 4H), 3.06 (t, *J* = 4.8 Hz, 4H). HR-ESI-MS: $m/z = 503.2010 [M+H]^+$, calcd for C₂₇H₂₅N₆O₂F₂: 503.2002.

Compound 11j: yield: 69%, mp: 227-228°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 10.05 (s, 1H), 9.39 (d, *J* = 3.6 Hz, 1H), 8.13 (d, *J* = 3.6 Hz, 2H), 7.78-7.83 (m, 3H), 7.65 (d, *J* = 8.4 Hz, 2H), 7.44 (d, *J* = 7.5 Hz, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.09 (t, *J* = 8.7 Hz, 2H), 6.90 (d, *J* = 8.7 Hz, 2H). HR-ESI-MS: $m/z = 448.1591 [M+H]^+$, calcd for C₂₄H₂₀N₅O₂F₂: 448.1580.

Compound 11k: yield:47 %, mp:214-216°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 10.09 (s, 1H), 9.40 (s, 1H), 8.13 (s, 2H), 7.78-7.81 (m, 3H), 7.42 (t, *J* = 7.5 Hz, 1H), 7.36 (t, *J* = 7.5 Hz, 1H), 7.07-7.13 (m, 4H), 6.25 (s, 1H), 3.72 (s, 6H). HR-ESI-MS: *m*/*z* = 478.1697 [M+H]⁺, calcd for C₂₅H₂₂N₅O₃F₂: 478.1685.

Compound 111: yield: 45%, mp: 224-226°C, ¹H-NMR (300 MHz, DMSO- d_6): δ 10.07 (s, 1H), 9.39 (s, 2H), 8.12 (t, J = 3.9 Hz, 2H), 7.78-7.82 (m, 3H), 7.41 (t, J = 1.8 Hz, 2H), 7.35 (t, J = 7.8 Hz, 1H), 7.16 (dd, J = 2.1, 8.4 Hz, 1H), 7.09 (t, J = 9.0 Hz, 2H), 6.87 (d, J = 8.4 Hz, 1H), 5.99 (s, 2H). HR-ESI-MS: m/z = 462.1383 [M+H]⁺, calcd for C₂₄H₁₈N₅O₃F₂: 462.1372.

Compound 11m: yield: 25%, mp: 224-226°C, ¹H-NMR (300 MHz, CD₃OD): δ 8.13 (s, 1H), 7.87 (d, J = 3.0 Hz, 1H), 7.65 (d, J = 1.5 Hz, 2H), 7.56-7.60 (m, 3H), 7.38 (d, J = 7.2 Hz, 1H), 7.28 (t, J = 7.5 Hz, 1H), 7.10 (s, 1H), 6.88 (t, J = 8.7 Hz, 2H). HR-ESI-MS: m/z = 486.0710 [M+H]⁺, calcd for C₂₃H₁₆N₅OF₂Cl₂: 486.0695.

Compound 11n: yield: 26%, mp: 131-133°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 10.58 (s, 1H), 9.39 (d, *J* = 5.7 Hz, 2H), 8.36 (d, *J* = 3.6 Hz, 1H), 8.12-8.19 (m, 3H), 7.77-7.86 (m, 4H), 7.74 (d, *J* = 7.8 Hz, 1H), 7.30 (t, *J* = 8.1 Hz, 1H), 7.05-7.16 (m, 3H). HR-ESI-MS: *m/z* = 419.1426 [M+H]⁺, calcd for C₂₂H₁₇N₆OF₂: 419.1426.

Compound 110: yield: 100%, mp: > 285°C, ¹H NMR(300MHz, DMSO-*d*₆): δ 9.32 (s, 1H), 9.18 (s, 1H), 8.23 (s, 1H), 8.09 (d, *J* = 3.6 Hz, 1H), 7.88-7.84 (m, 2H), 7.67 (d, *J* = 7.5 Hz, 2H), 7.20-7.18 (m, 2H), 7.15-7.07 (m, 3H), 6.60 (s, 1H). HR-ESI-MS: *m/z* = 425.0984[M+H]⁺, calcd for C₂₀H₂₁N₂O₅: 425.0991.

Compound 11p:yield: 48%, mp: 221-223°C, ¹H-NMR (300 MHz, DMSO-*d*₆): δ 10.06 (s, 1H), 9.36 (s, 1H), 9.23 (s, 1H), 8.10 (d, *J* = 3.6 Hz, 1H), 8.03 (s, 1H), 7.82 (dd, *J* = 4.8, 9.0 Hz, 2H), 7.07-7.43 (m, 7H), 3.96 (s, 3H). HR-ESI-MS: *m/z* = 422.1538 [M+H]⁺, calcd for C₂₁H₁₈N₇OF₂: 422.1535.

3.3 Biological evaluation

3.3.1 Cytotoxic activity assay

The following human tumor cell lines were used in the assay: A549 (lung cancer), DU-145 (prostate cancer), KB (nasopharyngeal carcinoma) and KBvin (vincristine-resistant KB subline). All cell lines were obtained from the Lineberger Comprehensive Cancer Center (UNC-CH) or from ATCC (Rockville, MD) and were cultured in RPMI-1640 medium supplemented with 25 mM HEPES, 0.25% sodium bicarbonate, 10% fetal bovine serum, and 100 mg/mL kanamycin.

The cytotoxicity assay was performed by following experimental protocols described in the reference²⁴. Freshly trypsinized cell suspensions were seeded in 96-well microtiter plates at densities of 1500-7500 cells per well with compounds added from DMSO-diluted stock. After 3 days in culture, attached cells were fixed with cold 50% trichloroacetic acid and then stained with 0.4% sulforhodamine B (SRB). The absorbance at 562 nm was measured using a microplate reader after solubilizing the bound dye. The mean IC₅₀ is the concentration of agents that reduces cell growth by

50% under the experimental conditions and it is the average from three independent determinations that are reproducible and statistically significant.

3.3.2 CDK2/Cyclin E1 kinase assay

Published on 28 November 2014. Downloaded by Northeastern University on 29/11/2014 11:08:35

The kinase assay against CDK2/cyclinE1 was performed by following experimental protocols described in the reference²⁵. The compounds were mixed with the enzyme (2.28 ng) in a buffer containing 40 mM Hepes/Tris(pH 7.4), 0.8 mM EGTA/Tris, 8 mM MgCl₂, 1.6 mM DTT and 0.008% Tween 20. Thereafter, the reaction was initiated by adding 100 nM of the substrate Ulight-CFFKNIVTPRTPPPSQGK-amide (MBP) and 10 μ M ATP, and the mixture was incubated for 15 minutes at room temperature. For control basal measurements, the enzyme was omitted from the reaction mixture. Following incubation, the reaction was stopped by adding 13 mM EDTA. After 5 minutes, the anti-phospho-MBP antibody labeled with europium chelate was added. After 60 more minutes, the fluorescence transfer was measured at λ ex=337 nm, λ em=620 nm and λ em=665 nm using a microplate reader (Envision, Perkin Elmer). The enzyme activity was determined by dividing the signal measured at 665 nm by that measured at 620 nm (ratio). The results were expressed as a percent inhibition of the control enzyme activity. The compounds were tested in each experiment at several concentrations to obtain an inhibition curve from which the IC₅₀ values were calculated.

3.3.3 CDK9/Cyclin T1 kinase assay

The kinase assay against CDK9/cyclinT1 was performed by following experimental protocols described in the reference²⁶. The compounds were mixed with the enzyme (21.72 ng) in a buffer containing 40 mM Hepes/Tris(pH 7.4), 0.8 mM EGTA/Tris, 8 mM MgCl₂, 1.6 mM DTT and 0.008% Tween 20. Thereafter, the reaction was initiated by adding 100 nM of the substrate Ulight-CFFKNIVTPRTPPPSQGK-amide (MBP) and 10 μ M ATP, and the mixture was incubated for 90 minutes at room temperature. For control basal measurements, the enzyme was omitted from

the reaction mixture. Following incubation, the reaction was stopped by adding 13 mM EDTA. After 5 minutes, the anti-phospho-MBP antibody labeled with europium chelate was added. After 60 more minutes, the fluorescence transfer was measured at $\lambda ex=337$ nm, $\lambda em=620$ nm and $\lambda em=665$ nm using a microplate reader (Envision, Perkin Elmer). The enzyme activity was determined by dividing the signal measured at 665 nm by that measured at 620 nm (ratio). The results were expressed as a percent inhibition of the control enzyme activity. The compounds were tested in each experiment at several concentrations to obtain an inhibition curve from which the IC₅₀ values were calculated.

3.3.4 Anti-HIV-1 assay

The anti-HIV-1 assay was performed with NL4-3 virus by following experimental protocols described in the reference²⁷. A 96-well microtiter plate was used to set up the HIV-1 NL4-3 replication assay. HIV-1 NL4-3 at a multiplicity of infection (MOI) of 0.01 was used to infect MT4 cells. Culture supernatants were collected on day 4 post infection for the p24 assay using an ELISA kit from ZeptoMetrix Corporation (Buffalo, New York).

3.4 Molecular modeling

The structures of compounds **6d** and **9g** were generated and molecular docking was performed with the Discovery Studio 2.5 software package (Accelrys, San Diego, USA). The structures of CDK2 and CDK9 were obtained from the Protein Data Bank (PDB codes: 4BCP and 4BCG). The docking calculation was carried out with the CDOCK protocol. Default settings were used. All calculations were performed on a DELL Precision T5500 workstation.

4. Conclusions

Thirty novel 5-fluoro- N^2 , N^4 -diphenylpyrimidine-2,4-diamine derivatives were designed as potential CDK, especially CDK9 inhibitors. Cytotoxicity for all the target compounds was measured with the

SRB assay. Compounds with GI₅₀ values against tumor cells at lower micromolar to submicromolar level were identified. Some most cytotoxic compounds exhibited potent inhibitory activities against both CDK2/cyclin E1 and CDK9/cyclin T1. Good correlation between cellular and molecular activities was observed. Noticeable inhibition against HIV-1 replication was also detected in an anti-HIV-1 assay, and there appeared to be a correlation between selective CDK9 inhibition and the anti-HIV-1 therapeutic index. Docking studies on this compound class hinted the existence of alternative binding poses and explained the realization of isotype selectivity, which provided new clues for further structural optimization.

Acknowledgements

Published on 28 November 2014. Downloaded by Northeastern University on 29/11/2014 11:08:35

This investigation was supported by the National Natural Science Foundation of China (81172985 and 81261120391) awarded to Z. Xiao. Partial support was also provided by NIH grants CA177584 from the National Cancer Institute and AI 033066 from the National Institute of Allergy and Infectious Disease awarded to K.H. Lee.

Notes and references:

- 1. S. Lim and P. Kaldis, *Development*, 2013, 140, 3079-3093.
- 2. J. Cicenas and M. Valius, J. Cancer Res. Clin. Oncol., 2011, 137, 1409-1418.
- 3. S. Wang and P. M. Fischer, *Trends Pharmacol. Sci.*, 2008, 29, 302-313.
- D. Salerno, M. G. Hasham, R. Marshall, J. Garriga, A. Y. Tsygankov and X. Graña, *Gene*, 2007, 405, 65-78.
- A. Ali, A. Ghosh, R. S. Nathans, N. Sharova, S. O'Brien, H. Cao, M. Stevenson and T. M. Rana, *ChemBioChem*, 2009, 10, 2072-2080.
- G. Németh, Z. Varga, Z. Greff, G. Bencze, A. Sipos, C. Szántai-Kis, F. Baska, Á. Gyuris, K. Kelemenics, Z. Szathmáry, J. Minárovits, G. Kéri and L. Őrfi, *Curr. Med. Chem.*, 2011, 18,

342-358.

- G. Németh, Z. Greff, A. Sipos, Z. Varga, R. Székely, M. Sebestyén, Z. Jászay, S. Béni, Z. Nemes, J.-L. Pirat, J.-N. Volle, D. Virieux, Á. Gyuris, K. Kelemenics, É. Áy, J. Minarovits, S. Szathmary, G. Kéri and L. Őrfi, *J. Med. Chem.*, 2014, **57**, 3939-3965.
- H. Shao, S. Shi, S. Huang, A. J. Hole, A. Y. Abbas, S. Baumli, X. Liu, F. Lam, D. W. Foley, P. M. Fischer, M. Noble, J. A. Endicott, C. Pepper and S. Wang, *J. Med. Chem.*, 2013, 56, 640-659.
- 9. T. K. Albert, C. Rigault, J. Eickhoff, K. Baumgart, C. Antrecht, B. Klebl, G. Mittler and M. Meisterernst, *Br. J. Pharmacol.*, 2014, **171**, 55-68.
- 10. S. Baumli, J. A. Endicott and L. N. Johnson, Chem. Biol., 2010, 17, 931-936.
- 11. S. Baumli, A. J. Hole, M. E. Noble and J. A. Endicott, ACS Chem. Biol., 2012, 7, 811-816.
- 12. A. J. Hole, S. Baumli, H. Shao, S. Shi, S. Huang, C. Pepper, P. M. Fischer, S. Wang, J. A. Endicott and M. E. Noble, *J. Med. Chem.*, 2013, **56**, 660-670.
- Z. Debebe, T. Ammosova, D. Breuer, D. B. Lovejoy, D. S. Kalinowski, P. K. Karla, K. Kumar, M. Jerebtsova, P. Ray, F. Kashanchi, V. R. Gordeuk, D. R. Richardson and S. Nekhai. *Mol. Pharmacol.*, 2011, **79**, 185-196.
- D. Breuer, A. Kotelkin, T. Ammosova, N. Kumari, A. Ivanov, A. V. Ilatovskiy, M. Beullens, P. R. Roane, M. Bollen, M. G. Petukhov, F. Kashanchi and S. Nekhai, *Retrovirology*, 2012, 9, 94.
- 15. C. Fang, Z. Xiao and Z. Guo, J. Mol. Graph. Model., 2011, 29, 800-8008.
- S. H. Chao, K. Fujinaga, J. E. Marion, R. Taube, E. A. Sausville, A. M. Senderowicz, B. M. Peterlin and D. H. Price, *J. Biol. Chem.*, 2000, 275, 28345–28348.
- S. Baumli, G. Lolli, E. D. Lowe, S. Troiani, L. Rusconi, A. N. Bullock, J. E. Debreczeni, S. Knapp S and L. N. Johnson, *EMBO J.*, 2008, 27, 1907-1918.
- C. D. Jones, D. M. Andrews, A. J. Barker, K. Blades, P. Daunt, S. East, C. Geh, M. A. Graham, K. M. Johnson, S. A. Loddick, H. M. McFarland, A. McGregor, L. Mossa, D. A. Rudge, P. B. Simpson, M. L. Swain, K. Y. Tama, J. A. Tucker and M. Walker, *Bioorg. Med. Chem. Lett.*, 2008,

18, 6369-6373.

Published on 28 November 2014. Downloaded by Northeastern University on 29/11/2014 11:08:35

- S. Wang, G. Griffiths, C. A. Midgley, A. L. Barnett, M. Cooper, J. Grabarek, L. Ingram, W. Jackson, G. Kontopidis, S. J. McClue, C. McInnes, J. McLachlan, C. Meades, M. Mezna, I. Stuart, M. P. Thomas, D. I. Zheleva, D. P. Lane, R. C. Jackson, D. M. Glover, D. G. Blake and P. M. Fischer, *Chem. Biol.*, 2010, 17, 1111-1121.
- 20. D. Ma, Q. Cai and H. Zhang, Org. Lett., 2003, 5, 2453-2455.
- T. Wang, M. L. Lamb, D. A. Scott, H. Wang, M. H. Block, P. D. Lyne, J. W. Lee, A. M. Davies,
 H.-J. Zhang, Y. Zhu, F Gu, Y. Han, B. Wang, P. J. Mohr, R. J. Kaus, J. A. Josey, E. Hoffmann, K.
 Thress, T. Macintyre, H. Wang, C. A. Omer and D. Yu, *J. Med. Chem.*, 2008, 51, 4672-4684.
- 22. E. J. Pease, E. J. Williams, R. H. Bradbury, S. E. Pearson, US Patent, 2003, US6649608B2.
- 23. M. D. Wendt, A. Geyer, W. J. McClellan, T. W. Rockway, M. Weitzberg and X. Zhao, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 3063-3068.
- 24. M. V. B. Reddy, Y.-C. Shen, E. Ohkoshi, K. F. Bastow, K. Qian, K.-H. Lee and T.-S. Wu, *Eur. J. Med. Chem.* 2012, **47**, 97-103.
- 25. L. Meijer, A. Borgne, O. Mulner, J. P. J. Chong, J. Blow, N. Inagaki, M. Inagaki, J. G. Delcros and J. P. Moulinoux, *Eur. J. Biochem.*, 1997, 243, 527-536.
- 26. G. de Falco and A. Giordano, J. Cell. Physiol., 1998, 177, 501-506.
- 27. L. Huang, P. Ho, K.-H. Lee and C.-H. Chen, Bioorg. Med. Chem., 2006, 14, 2279-2289.